Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity

Cancer Research

Volumn 58, Issue 2, 1998, Pages 195-197

  Herman, Eugene H ^a   Lipshultz, Steven E ^b   Rifai, Nader ^c   Zhang, Jun ^a   Papoian, Thomas ^a   Yu, Zu Xi ^d   Takeda, Kazuyo ^d   Ferrans, Victor J ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; TROPONIN T;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; IMMUNOHISTOCHEMISTRY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOXORUBICIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEART; HEART DISEASES; HYPERTENSION; MYOCARDIUM; RATS; RATS, INBRED SHR; TROPONIN; TROPONIN T;

EID: 0031974196     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Carrio, I., Estorch, M., and Lopez-Pousa, A. Assessing anthracycline cardiotoxicity in the 1990s. Eur. J. Nucl. Med., 23: 359-364, 1996.
2. Ganz, W. I., Sridhar, K. S., Ganz, S. S., Gonzalez, R., Chakko, S., and Serafini, A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology (Basel), 53: 461-470, 1996.
3. Mair, J., Dienstl, F., and Puschendo, F. B. A. Cardiac troponin-T in the diagnosis of myocardial injury. Crit. Rev. Clin. Lab. Sci., 29: 31-57, 1992.
4. Herman, E. H., El-Hage, A., and Ferrans, V. J. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol. Appl. Pharmacol. 92: 42-53, 1988.
5. Billingham, M. E. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: M. D. Silver (ed.). Cardiovascular Pathology, pp. 1465-1486. New York: Churchill-Livingstone, Inc., 1991.
6. Herman, E. H., and Ferrans, V. J. Pathophysiology of anthracycline cardiotoxicity. In: J. T. Bricker, D. M. Green, G. J. D'Angio (eds.). Cardiac Toxicity after Treatment for Childhood Cancer, pp. 25-34. New York: Wiley-Liss, 1993.
7. Fink, F. M., Genser, N., Fink, C., Falk, M., Mair, J., Maurer-Dengg, K., Hammerer, I., and Puschendorf, B. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediatr. Oncol., 25: 185-189, 1995.
8. Ottlinger, M. E., Sallan, S., Rifai, N., Sacks, D. G., and Lipshultz, S. E. Myocardial damage in doxorubicin-treated children: a study of serum cardiac troponin T. Proc. Am. Soc. Clin. Oncol., 14: 345, 1995.
9. Lipshultz, S. E., Ottlinger, M., Lipsitz, S. R., Sallan, S. E., Sachs, D., and Rafai, N. Predictive value of serum cardiac troponin T (cTnT) in pediatric patients at risk for myocardial injury. J. Am. Coll. Cardiol., 29: 429A, 1997.
10. Seino, Y., Tomita, Y., Nagai, Y., Kusama, Y., Hayakawa, H., Sasaki, T., and Horii, I. Cardioprotective effects of ACE-inhibitor (Cilazapril) on Adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation, 88: 1633, 1993.
11. Missov, E., Pau, B., and Calzolari, C. Increased circulating levels of cardiac troponin-I in anthracycline-treated patients. Circulation, 94: 4282, 1996.